NewTimeSpace News: On June 25, 2026, RoboSense (02498.HK) trended weaker in the afternoon trading session. As of 14:22, its intraday quotation stood at HK$21.32, representing a drop of 3.44%. The large-scale commercial adoption of high-level intelligent driving is expected to pick up speed.
NewTimeSpace (newtimespace.com) News: On June 25, 2026, the chip sector continued to strengthen. ASMPT(00522.HK) opened higher and fluctuated. As of 13:38 PM, the company's share price was quoted at HK$202.200, up 0.70%.
NewTimeSpace (newtimespace.com) News: On June 25, 2026, the humanoid robot sector weakened.Xiaomi-W (01810.HK) fluctuated and weakened. As of 13:13 PM, the company's share price was quoted at HK$22.200, down 3.31%.
NewTimeSpace (newtimespace.com) News, The inaugural Beijing-Birmingham Technology Week was held in Beijing, and Mininglamp Technology (2718.HK) was one of the four Beijing sci-tech enterprises invited to participate in the event. The company expressed its willingness to enter the UK market and deepen industrial cooperation, and secured the opportunity to participate in the main event of Birmingham Tech Week this October.
NewTimeSpace (newtimespace.com) News: On June 25, 2026, despite the weakening of the Hang Seng Tech Index, Hong Kong's artificial intelligence-themed stocks bucked the trend to strengthen. Zhipu (2513.HK) led the gains; as of 9:50 AM, the company's share price was quoted at HK$2,352.000, up 8.19%.
NewTimeSpace News: HUTCHMED announced on June 25 that results from its pivotal Phase II registrational study of fisogatinib for the treatment of intrahepatic cholangiocarcinoma are set to be unveiled at the 2026 ESMO Gastrointestinal Cancers Congress.
NewTimeSpace News: Mabwell announced on June 24 that the clinical trial application for its self-developed Injection 9MW5211 for the indication of multiple sclerosis (MS) has been approved by the National Medical Products Administration (NMPA).
Mabpharm (2181.HK) announced that its pipeline product CMAB807X Leishu® (denosumab injection) has received NMPA approval for its NDA, with indications covering the treatment of solid tumor bone metastasis or multiple myeloma patients to delay or reduce skeletal-related event risks, and giant cell tumor of bone that is unresectable or where surgery would cause severe morbidity, including adults and skeletally mature adolescents.
On June 24, Hong Kong stocks fluctuated higher, driven by a broad rally in the semiconductor sector, where Hua Hong Semiconductor skyrocketed over 15% to an all-time high following acquisition approvals. AI application stocks diverged: Tencent advanced 3.4% as its WeCom AI Agent entered closed beta, while MiniMax continued to decline. Industry developments highlighted that over 900 large models are now operational in China, with regulators drafting new AI agent guidelines. Meanwhile, Alibaba launched Qwen-AgentWorld, the first native language world model, and Mininglamp rolled out its "Agent Ready" solution, integrating with WeChat and Qwen to accelerate enterprise AI commercialization.
NewTimeSpace (newtimespace.com) News: On June 24, 2026, the chip sector strengthened as SMIC (00981.HK) surged significantly. As of 13:21 PM, the company's share price was quoted at HK$85.600, up 9.96%.
NewTimeSpace (newtimespace.com) News:On June 24, 2026, the humanoid robot sector fluctuated and weakened. UBTECH (09880.HK) fluctuated downward, with the company's share price quoted at HK$97.950, edging down by 0.05% as of 13:09 PM.
NewTimeSpace News: On June 24, 2026, XPENG-W(09868.HK) trended slightly higher in the morning session. As of 10:50, the stock was quoted at HK$49.76, representing an increase of 0.81%. The company showcased its full-stack technological achievements in physical AI at the 4th China International Supply Chain Expo.
NewTimeSpace (newtimespace.com) News, on June 24, 2026, Mininglamp Technology (2718.HK) surged during morning trading. As of 10:06 AM, the company's share price was quoted at HK$240.600, up 7.89%.Relying on its multi-industry scenario knowledge bases, massive text corpora of real consumer intents, and extensive cross-platform engineering experience, Mininglamp Technology (2718.HK) has initiated integration practices with AI platforms such as WeChat and Tongyi Qianwen, comprehensively launching its Agent Ready solutions tailored for brand clients.
On June 23, Hong Kong stocks suffered a broad decline, triggering a sharp correction in the LLM and semiconductor sectors. MINIMAX plunged over 16% ahead of its impending lock-up expiration, while ZHIPU AI dropped 10%. On the industry front, both infrastructure development and commercial applications accelerated: Intel launched its "AI Home Brain" with domestic tech giants to propel the smart home ecosystem; Volcano Engine revealed Doubao's daily volume exceeded 180 trillion tokens alongside the release of Doubao 2.1 Pro; and DeepSeek established a dedicated "Harness" group to systematically build out its Agent infrastructure and product capabilities.
NewTimeSpace News: Sino Biopharmaceutical Limited (01177.HK) announced on 23 June that the New Drug Application (NDA) for its CLDN18.2 ADC innovative drug Tecotabart Vedotin has been accepted by authorities for third-line and above gastric cancer treatment and has been granted priority review. The drug can precisely target CLDN18.2-positive tumors and exert bystander killing effect, with synergistic anti-tumor efficacy when combined with PD-1 antibody. Approximately 970,000 new gastric cancer cases are diagnosed globally each year, over one third of which occur in China, and CLDN18.2 represents a popular therapeutic target. A Phase III clinical trial of the ADC combined with PD-1 antibody for first-line treatment is also underway.
NewTimeSpace News: Sino Biopharmaceutical Limited (01177.HK) announced on 23 June that its Class 1 innovative drug Pelecanam Spray (trade name: Puyike®) has obtained marketing approval from the National Medical Products Administration (NMPA), indicated for secondary wound infection resulting from burns and scalds. As a first-in-class ganan-class anti-infective agent globally, it delivers potent bactericidal efficacy against multiple drug-resistant bacteria. Key clinical trials demonstrated its therapeutic effect significantly outperforms the control group. Chia Tai Tianqing holds the exclusive commercialization rights for the product in China.
